spacer
home > pmps > autumn 2003 > environmental monitoring practices and regulations for the sterile manufacturer
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Environmental Monitoring Practices and Regulations for the Sterile Manufacturer

Manufacturing of pharmaceutical products and medical devices requires an environment in which the number of airborne particles is controlled, and which is constructed and used in a manner to minimise the introduction, generation and retention of such particles. Other relevant parameters such as temperature, humidity, airflow filtration, and velocity and room pressurisation, are controlled as necessary. A formal programme is established and maintained to assess these factors and their effect on the microbiological quality of the process and product. Due to minor differences in the requirements of regulating agencies (see Tables 1-3), the programme should be established with reference to those regulatory requirements in the country in which the products will be sold.

Luckily, a plethora of standards and guidelines are now available to help manufacturers. In the US the FDA's Quality Systems Regulation states '...the manufacturer shall establish and maintain procedures to adequately control these environmental conditions', and '...procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality'. IEST has promulgated several ISO standards (see Table 4), incorporating information from the now defunct Federal Standard 209E. In addition, the FDA's Aseptic Processing Guideline (1987) discusses where to monitor non-viable particulate and states that samples should be taken Ònot more than one foot away from the worksite'. In 2001 PDA published technical report No. 13, Fundamentals of an Environmental Monitoring Program, a very complete summary of the fundamentals.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Anne Booth, Quality GMP and Sterilisation Specialist at Booth Scientific

Anne F Booth is a Quality GMP and Sterilization Specialist with over 20 years' of experience in the field of medical device manufacturing. She has worked for three medical device manufacturers as Sterilisation Services Manager/Director and a contract steriliser as Director of Validation. In each of these positions she provided technical support in the development, validation and management of both GMP compliance and sterilisation programmes. Ms Booth's experience has also included establishing sterilisation support testing labs and environmental monitoring programmes, developing quality manuals and performing audits, validating cleanrooms and manufacturing processes, and recommending cleaning and sterilisation programmes for reusable devices. She established an independent consulting business, Booth Scientific Inc, in 1994 which has provided optimal GMP and sterilisation programmes for more than 50 medical device and pharmaceutical manufacturers.

She holds a MS degree in Cellular Zoology/Biochemistry from the University of Michigan and a BA degree in Biology from Wilson College. She is a Member of the American Society of Quality, RAPS, PDA, ISPE and AAMI where she is a Member of the EtO sterilisation, EtO Residual, Packaging, Radiation, Microbiological Methods and Reuse standards working groups. Ms Booth is also widely published.

spacer
Anne F Booth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement